Ram Z, Walbridge S, Shawker T, Culver K W, Blaese R M, Oldfield E H
Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.
J Neurosurg. 1994 Aug;81(2):256-60. doi: 10.3171/jns.1994.81.2.0256.
Eradication of malignant brain tumors by in situ intratumoral, retrovirally mediated transfer of the herpes simplex virus thymidine kinase (HSVtk) gene, which sensitizes the tumor cells to ganciclovir, has recently been demonstrated in animal models. The observation that tumors studied in vitro and in animals can be completely eliminated despite only partial transduction of the tumor suggests a bystander mechanism that affects nontransduced tumor cells. Such a bystander effect is not completely understood and may represent a combination of several factors that lead to tumor eradication. Endothelial cells of the tumor blood vessels were shown to occasionally integrate the retroviral vector and thus become sensitized to ganciclovir. In the presence of vector-producer cells, which continuously release infectious viral particles, diffuse multifocal hemorrhages occurred during ganciclovir administration. When the tumor was composed of cells that had been transduced with the thymidine kinase gene before inoculation, no infectious viral particles were present within the tumor, no transduction of endothelial cells occurred, and no hemorrhages were observed during ganciclovir therapy. These observations suggest that tumor regression may be due, in part, to destruction of in vivo HSVtk-transduced endothelial cells after exposure to ganciclovir, resulting in tumor ischemia as one possible bystander mechanism. The authors investigated this hypothesis using the subcutaneous 9L gliosarcoma tumor model in Fischer rats. The tumors were evaluated with Doppler color-flow and ultrasound imaging during the various phases of the study. Twenty rats received intratumoral injections of HSVtk retroviral vector-producer cells (6 x 10(7) cells/ml) 21 days after bilateral flank tumor inoculation. Ten rats were subsequently treated with intraperitoneal ganciclovir (15 mg/kg/ml twice a day) for 14 days starting on Day 7 after producer cell injection; 10 control rats received intraperitoneal saline injections (1 ml twice a day) instead of ganciclovir. Ultrasound and flow images were obtained before cell injection, before and during ganciclovir or saline administration, and after cessation of treatment. The number, location, and ultrasonographic appearance of tumor vessels and the tumor volumes were recorded. The number of blood vessels in the tumors increased over time in both groups before treatment. Intratumoral cell injection without ganciclovir administration did not influence tumor growth or intratumoral vasculature. However, tumor vasculature decreased after initiation of ganciclovir therapy in the HSVtk-transduced tumors (p < 0.05). Early patchy or diffuse necrotic changes associated with ultrasonographic evidence of scattered intratumoral hemorrhage occurred in tumors treated with ganciclovir.(ABSTRACT TRUNCATED AT 400 WORDS)
通过瘤内原位逆转录病毒介导的单纯疱疹病毒胸苷激酶(HSVtk)基因转移来根除恶性脑肿瘤,该基因可使肿瘤细胞对更昔洛韦敏感,最近已在动物模型中得到证实。在体外和动物研究中观察到,尽管肿瘤仅部分转导,但仍可被完全消除,这提示存在一种影响未转导肿瘤细胞的旁观者机制。这种旁观者效应尚未完全明确,可能是多种导致肿瘤根除的因素共同作用的结果。已表明肿瘤血管内皮细胞偶尔会整合逆转录病毒载体,从而对更昔洛韦敏感。在存在持续释放感染性病毒颗粒的载体产生细胞的情况下,给予更昔洛韦期间会发生弥漫性多灶性出血。当肿瘤由接种前已用胸苷激酶基因转导的细胞组成时,肿瘤内不存在感染性病毒颗粒,内皮细胞未发生转导,且在更昔洛韦治疗期间未观察到出血现象。这些观察结果表明,肿瘤消退可能部分归因于暴露于更昔洛韦后体内HSVtk转导的内皮细胞被破坏,导致肿瘤缺血,这是一种可能的旁观者机制。作者使用Fischer大鼠皮下9L胶质肉瘤肿瘤模型对这一假设进行了研究。在研究的各个阶段,用多普勒彩色血流和超声成像对肿瘤进行评估。双侧胁腹接种肿瘤21天后,20只大鼠接受瘤内注射HSVtk逆转录病毒载体产生细胞(6×10⁷细胞/毫升)。10只大鼠在注射产生细胞后第7天开始,随后接受腹腔注射更昔洛韦(15毫克/千克/毫升,每日两次),持续14天;10只对照大鼠接受腹腔注射生理盐水(1毫升,每日两次)而非更昔洛韦。在细胞注射前、更昔洛韦或生理盐水给药前及给药期间以及治疗停止后获取超声和血流图像。记录肿瘤血管的数量、位置和超声表现以及肿瘤体积。两组在治疗前肿瘤血管数量均随时间增加。未给予更昔洛韦的瘤内细胞注射不影响肿瘤生长或瘤内血管系统。然而,在HSVtk转导的肿瘤中,更昔洛韦治疗开始后肿瘤血管系统减少(p<0.05)。接受更昔洛韦治疗的肿瘤出现与瘤内散在出血的超声证据相关的早期斑片状或弥漫性坏死改变。